Mach-1 Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Mach-1 Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,807	Closed	-$735K	–	218
2023 Q4	$735K	Buy	+1,807	New	+$668K	0.28%	84
2023 Q1	–	Sell	-2,805	Closed	-$810K	–	346
2022 Q4	$810K	Buy	+2,805	New	+$855K	0.27%	75

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Mach-1 Financial Group's VRTX Position: Q1 2024 in Review

Mach-1 Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 1,807 shares — an estimated $735K sold.

Mach-1 Financial Group first reported a position in VRTX in Q4 2022 and held it in 2 quarters. The position peaked at $810K in Q4 2022. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Mach-1 Financial Group reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Mach-1 Financial Group sold 1,807 Vertex Pharmaceuticals shares in Q1 2024, an estimated $735K.
Mach-1 Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 2 quarters.
Mach-1 Financial Group's Vertex Pharmaceuticals position peaked at $810K in Q4 2022.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Mach-1 Financial Group's 13F filing for Q1 2024, filed 10 May 2024.